DK2619331T3 - METHODS OF CANCER TREATMENT COMPREHENSIVE TO TARGET NQO1 - Google Patents

METHODS OF CANCER TREATMENT COMPREHENSIVE TO TARGET NQO1 Download PDF

Info

Publication number
DK2619331T3
DK2619331T3 DK11827555.1T DK11827555T DK2619331T3 DK 2619331 T3 DK2619331 T3 DK 2619331T3 DK 11827555 T DK11827555 T DK 11827555T DK 2619331 T3 DK2619331 T3 DK 2619331T3
Authority
DK
Denmark
Prior art keywords
cells
cancer
lap
catalase
fold
Prior art date
Application number
DK11827555.1T
Other languages
Danish (da)
English (en)
Inventor
David Boothman
Erik Bey
Ying Dong
Jinming Gao
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of DK2619331T3 publication Critical patent/DK2619331T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK11827555.1T 2010-09-22 2011-09-22 METHODS OF CANCER TREATMENT COMPREHENSIVE TO TARGET NQO1 DK2619331T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38541110P 2010-09-22 2010-09-22
PCT/US2011/052801 WO2012040492A1 (en) 2010-09-22 2011-09-22 Methods of treating cancer comprising targeting nqo1

Publications (1)

Publication Number Publication Date
DK2619331T3 true DK2619331T3 (en) 2018-06-06

Family

ID=45874170

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11827555.1T DK2619331T3 (en) 2010-09-22 2011-09-22 METHODS OF CANCER TREATMENT COMPREHENSIVE TO TARGET NQO1

Country Status (10)

Country Link
US (1) US9469878B2 (enExample)
EP (1) EP2619331B1 (enExample)
DK (1) DK2619331T3 (enExample)
ES (1) ES2671248T3 (enExample)
HU (1) HUE037382T2 (enExample)
NO (1) NO2619331T3 (enExample)
PL (1) PL2619331T3 (enExample)
PT (1) PT2619331T (enExample)
TR (1) TR201807363T4 (enExample)
WO (1) WO2012040492A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9233960B2 (en) 2011-10-14 2016-01-12 The Board Of Trustees Of The University Of Illinois Compounds and anti-tumor NQO1 substrates
PT2984184T (pt) * 2013-04-09 2021-02-24 Univ Texas Utilização de dnq ou dnq-87 em combinação com um inibidor de parp1 para o tratamento do cancro
CN103667447A (zh) * 2013-11-04 2014-03-26 武汉艾迪康医学检验所有限公司 用于检测nqo1基因多态性的引物、试剂盒及其在病理检测上的应用
WO2019156684A1 (en) * 2018-02-12 2019-08-15 Solugen, Inc. Hydrogen peroxide production method, system, and apparatus
WO2020190990A1 (en) * 2019-03-18 2020-09-24 The Board Of Regents Of The University Of Texas System Tumor-selective combination therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2273688T3 (es) 1999-04-14 2007-05-16 Dana-Farber Cancer Institute, Inc. Procedimiento y composicion para el tratamiento de cancer.
JP4317452B2 (ja) * 2001-11-01 2009-08-19 スペクトラム・ファーマシューティカルス・インコーポレーテッド 膀胱癌の膀胱内処置用の医学的組成物
WO2003090710A1 (en) 2002-04-23 2003-11-06 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
WO2006020722A2 (en) 2004-08-11 2006-02-23 Arqule, Inc. Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
JP5457036B2 (ja) * 2006-02-09 2014-04-02 スペクトラム ファーマシューティカルズ インコーポレイテッド 腫瘍酵素レベルの決定を含む膀胱癌の処置
EP2131814A4 (en) 2007-02-26 2011-08-03 Wisconsin Alumni Res Found POLYMIC MICROMS FOR THE RELEASE OF ACTIVE COMPOUNDS
ES2626437T3 (es) 2010-09-22 2017-07-25 The Board Of Regents Of The University Of Texas System Copolímero en bloque novedoso y composiciones micelares y procedimientos de uso de las mismas

Also Published As

Publication number Publication date
US20130253046A1 (en) 2013-09-26
PT2619331T (pt) 2018-06-01
EP2619331A4 (en) 2014-03-05
WO2012040492A1 (en) 2012-03-29
EP2619331B1 (en) 2018-02-28
US9469878B2 (en) 2016-10-18
TR201807363T4 (tr) 2018-06-21
HUE037382T2 (hu) 2018-08-28
NO2619331T3 (enExample) 2018-07-28
PL2619331T3 (pl) 2018-10-31
EP2619331A1 (en) 2013-07-31
ES2671248T3 (es) 2018-06-05

Similar Documents

Publication Publication Date Title
Franqui-Machin et al. Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma
Zhang et al. NAD (P) H: quinone oxidoreductase 1 (NQO1) as a therapeutic and diagnostic target in cancer
Zhou et al. RETRACTED ARTICLE: Induction of apoptosis and autophagy via sirtuin1-and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells
Yan et al. Increased dopamine and its receptor dopamine receptor D1 promote tumor growth in human hepatocellular carcinoma
Kelly et al. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO‐dependent mechanism
Lin et al. Inhibition of mitochondria-and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells
Pratt et al. Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells
Huang et al. Nrf2 inhibition increases sensitivity to chemotherapy of colorectal cancer by promoting ferroptosis and pyroptosis
Rastogi et al. (6)-Gingerolinduced myeloid leukemia cell death is initiated by reactive oxygen species and activation of miR-27b expression
DK2619331T3 (en) METHODS OF CANCER TREATMENT COMPREHENSIVE TO TARGET NQO1
WO2014138101A1 (en) Gene signature to predict homologous recombination (hr) deficient cancer
Li et al. Remodeling serine synthesis and metabolism via nanoparticles (NPs)‐mediated CFL1 silencing to enhance the sensitivity of hepatocellular carcinoma to sorafenib
Tian et al. Melatonin enhances sorafenib-induced cytotoxicity in FLT3-ITD acute myeloid leukemia cells by redox modification
WO2014092905A1 (en) Methods and assays for combination treatment of cancer
Gordon et al. Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes
US10676746B2 (en) Methods for identifying therapeutic targets and treating monitoring cancers
Zhang et al. Antifungal agent Terbinafine restrains tumor growth in preclinical models of hepatocellular carcinoma via AMPK-mTOR axis
Xiang et al. HIF-1-dependent heme synthesis promotes gemcitabine resistance in human non-small cell lung cancers via enhanced ABCB6 expression
Viera et al. DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition
Singh et al. Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells
Yu et al. Mitochondrial DNA depletion promotes impaired oxidative status and adaptive resistance to apoptosis in T47D breast cancer cells
Maser et al. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma
Kayahara et al. Pineal gland protects against chemically induced oral carcinogenesis and inhibits tumor progression in rats
Chen et al. LncRNA-ZFAS1 contributes to colon cancer progression through the miR-150-5p/VEGFA axis
Shui et al. Proteomics and bioinformatics analysis of lovastatin-induced differentiation in ARO cells